JO3002B1 - مركبات و تركيبات كمثبطات كيناز بروتين - Google Patents

مركبات و تركيبات كمثبطات كيناز بروتين

Info

Publication number
JO3002B1
JO3002B1 JOP/2010/0297A JOP20100297A JO3002B1 JO 3002 B1 JO3002 B1 JO 3002B1 JO P20100297 A JOP20100297 A JO P20100297A JO 3002 B1 JO3002 B1 JO 3002B1
Authority
JO
Jordan
Prior art keywords
compounds
compositions
protein kinase
kinase inhibitors
diseases
Prior art date
Application number
JOP/2010/0297A
Other languages
English (en)
Inventor
Tellew John
Poon Daniel
Wang Xing
Jin Xianming
Liu Zuosheng
Haung Shenlin
Wan Yongqin
Xie Yongping
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of JO3002B1 publication Critical patent/JO3002B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

يقدم الاختراع الحالي فئة جديدة من مركبات، تركيبات صيدلية تتضمن تلك المركبات و طرق لاستخدام تلك المركبات لعلاج او منع امراض او اضطربات مرتبطة بنشاط كيناز غير طبيعي و غير منتظم، و بصفة خاصة امراض اواضطرابات و التي تتضمن تنشيط غير طبيعي ب B-Raf
JOP/2010/0297A 2009-08-28 2010-08-26 مركبات و تركيبات كمثبطات كيناز بروتين JO3002B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
JO3002B1 true JO3002B1 (ar) 2016-09-05

Family

ID=42782253

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0297A JO3002B1 (ar) 2009-08-28 2010-08-26 مركبات و تركيبات كمثبطات كيناز بروتين

Country Status (50)

Country Link
US (12) US8501758B2 (ar)
EP (2) EP2470526B1 (ar)
JP (2) JP5475888B2 (ar)
KR (1) KR101413392B1 (ar)
CN (2) CN103896921B (ar)
AR (1) AR077975A1 (ar)
AU (1) AU2010286569C1 (ar)
BR (1) BR112012004453B1 (ar)
CA (1) CA2771775C (ar)
CL (1) CL2012000340A1 (ar)
CO (1) CO6612222A2 (ar)
CR (1) CR20120102A (ar)
CU (1) CU24110B1 (ar)
CY (3) CY1118452T1 (ar)
DK (2) DK2470526T3 (ar)
DO (1) DOP2012000051A (ar)
EA (2) EA201500175A1 (ar)
EC (2) ECSP12011700A (ar)
ES (2) ES2610825T3 (ar)
GE (1) GEP20146102B (ar)
GT (1) GT201200053A (ar)
HK (1) HK1167390A1 (ar)
HN (1) HN2012000441A (ar)
HR (2) HRP20140799T1 (ar)
HU (3) HUE032847T2 (ar)
IL (1) IL218084A (ar)
IN (1) IN2012DN02469A (ar)
JO (1) JO3002B1 (ar)
LT (3) LT2727918T (ar)
LU (1) LUC00101I2 (ar)
MA (1) MA33604B1 (ar)
ME (2) ME01860B (ar)
MX (1) MX2012002546A (ar)
MY (1) MY156259A (ar)
NI (1) NI201200029A (ar)
NL (1) NL300973I2 (ar)
NO (1) NO2019011I1 (ar)
NZ (1) NZ598924A (ar)
PE (1) PE20120861A1 (ar)
PL (2) PL2470526T3 (ar)
PT (2) PT2727918T (ar)
RS (2) RS53489B1 (ar)
SG (2) SG178351A1 (ar)
SI (2) SI2727918T1 (ar)
SM (2) SMT201400133B (ar)
TN (1) TN2012000081A1 (ar)
UA (1) UA112285C2 (ar)
UY (1) UY32860A (ar)
WO (1) WO2011025927A1 (ar)
ZA (1) ZA201202020B (ar)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
JP5933459B2 (ja) 2010-02-25 2016-06-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｒａｆ阻害剤に対する耐性を付与するｂｒａｆ突然変異
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
RU2622015C2 (ru) * 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
CA2856406C (en) * 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
US20130165464A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2673070T3 (es) 2012-03-28 2018-06-19 Dana-Farber Cancer Institute, Inc. Mutantes C-RAF que confieren resistencia a los inhibidores de RAF
EP2875021B1 (en) 2012-07-18 2017-08-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
RS58734B1 (sr) 2012-08-07 2019-06-28 Novartis Ag Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor
BR112015003418A2 (pt) 2012-08-17 2017-07-04 Hoffmann La Roche produto farmacêutico, conjunto, métodos para estender a duração da resposta ao tratamento, de retardar ou prevenir o desenvolvimento de resistência ao tratamento, para a seleção de uma terapia e para otimizar a eficácia terapêutica.
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
CN104994850A (zh) * 2012-11-08 2015-10-21 诺华股份有限公司 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
JP6449234B2 (ja) 2013-03-21 2019-01-09 ノバルティス アーゲー 併用療法
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
EP4043017A1 (en) * 2013-12-20 2022-08-17 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
CN107074828B (zh) * 2014-09-12 2020-05-19 诺华股份有限公司 用作raf激酶抑制剂的化合物和组合物
EP3659621A1 (en) 2014-09-13 2020-06-03 Novartis AG Combination therapies for cancer
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
KR20180107121A (ko) 2015-12-30 2018-10-01 세인트 루이스 유니버시티 팬 인테그린 길항제로서의 메타-아자사이클릭 아미노 벤조산 유도체
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
DK3463345T3 (da) 2016-06-03 2023-01-09 Array Biopharma Inc Farmaceutiske kombinationer
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CA3048376A1 (en) 2016-12-27 2018-07-05 Riken Bmp-signal-inhibiting compound
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
US11725185B2 (en) 2017-12-28 2023-08-15 University Of Houston System Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
EP3968995A1 (en) 2019-05-16 2022-03-23 Eli Lilly and Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
CN114746419B (zh) 2019-12-05 2023-10-24 国家医疗保健研究所 N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
EP4196228A1 (en) 2020-08-13 2023-06-21 Albert Einstein College of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
WO2022258612A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
AU7106996A (en) 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
ZA984358B (en) 1997-05-22 1999-05-24 Searle & Co Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PT1239831E (pt) 1999-12-23 2013-01-23 Mayne Pharma International Pty Ltd Composições farmacêuticas melhoradas para fármacos fracamente solúveis
US6756410B2 (en) 2000-08-30 2004-06-29 Kamal D. Mehta Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100954625B1 (ko) 2001-10-25 2010-04-27 노파르티스 아게 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물
AU2002356301A1 (en) 2001-12-21 2003-07-15 Cancer Research Technology Ltd. 3,4-diarylpyrazoles and their use in the therapy of cancer
AR038971A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
JP2007505938A (ja) 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
MXPA06007820A (es) 2004-01-09 2006-09-01 Novartis Ag Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
CN1960988B (zh) 2004-06-10 2012-01-25 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1871773A1 (en) 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
RU2442574C2 (ru) 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
EP2004165A2 (en) 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
US20080221132A1 (en) 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
PT2068880E (pt) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Método para tratamento do cancro apresentando mutações no egfr
EP2057146A1 (en) 2006-10-02 2009-05-13 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101522026A (zh) * 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
US20100069458A1 (en) 2007-02-15 2010-03-18 Peter Wisdom Atadja Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009016460A2 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
WO2009050291A2 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
WO2009062676A2 (en) 2007-11-14 2009-05-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI0908906A2 (pt) * 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009273197B2 (en) 2008-07-24 2014-01-16 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
WO2010034838A2 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
KR101668499B1 (ko) 2008-10-07 2016-10-21 아스트라제네카 유케이 리미티드 약학 제제 514
WO2010056662A1 (en) * 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
US8524707B2 (en) 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP3045457B1 (en) * 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
MX341728B (es) 2010-01-27 2016-08-30 Nerviano Medical Sciences S R L * Derivados sulfonamido de 3, 4/diarilpirazoles como inhibidores de proteina quinasa.
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
DK2688572T3 (en) 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
JP6200884B2 (ja) 2011-06-14 2017-09-20 ノバルティス アーゲー 骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
CN104994850A (zh) 2012-11-08 2015-10-21 诺华股份有限公司 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
MY156259A (en) 2016-01-29
DOP2012000051A (es) 2012-05-31
ME01860B (me) 2014-12-20
US20160280686A1 (en) 2016-09-29
ZA201202020B (en) 2012-12-27
PE20120861A1 (es) 2012-07-14
SG10201405311TA (en) 2014-09-26
HK1167390A1 (en) 2012-11-30
LUC00101I1 (ar) 2019-02-13
AU2010286569A1 (en) 2012-04-12
US10568884B2 (en) 2020-02-25
EP2727918B1 (en) 2016-10-12
ME02684B (me) 2017-06-20
CY2019013I1 (el) 2019-11-27
UY32860A (es) 2011-03-31
US10005761B2 (en) 2018-06-26
CR20120102A (es) 2012-05-02
PT2470526E (pt) 2014-09-01
NL300973I1 (ar) 2019-03-27
US9593100B2 (en) 2017-03-14
CU24110B1 (es) 2015-07-30
JP2013503186A (ja) 2013-01-31
LTPA2019006I1 (lt) 2019-03-25
US20200323852A1 (en) 2020-10-15
LT2727918T (lt) 2017-01-25
CN102725283B (zh) 2014-02-26
US10576080B2 (en) 2020-03-03
EP2470526B1 (en) 2014-05-28
CY2019014I2 (el) 2019-11-27
CY1118452T1 (el) 2017-07-12
US9850229B2 (en) 2017-12-26
UA112285C2 (uk) 2016-08-25
WO2011025927A1 (en) 2011-03-03
US20180297986A1 (en) 2018-10-18
US20110306625A1 (en) 2011-12-15
RS55568B1 (sr) 2017-05-31
IL218084A0 (en) 2012-04-30
HRP20170005T1 (hr) 2017-03-10
ES2610825T3 (es) 2017-05-03
US9850230B2 (en) 2017-12-26
JP5475888B2 (ja) 2014-04-16
CN103896921B (zh) 2016-02-24
HN2012000441A (es) 2015-01-05
CY2019014I1 (el) 2019-11-27
LTPA2019005I1 (lt) 2019-03-25
PL2727918T3 (pl) 2017-06-30
SMT201700036B (it) 2017-03-08
TN2012000081A1 (en) 2013-09-19
HUS1900012I1 (hu) 2019-04-29
CY2019013I2 (el) 2019-11-27
CN102725283A (zh) 2012-10-10
KR101413392B1 (ko) 2014-06-27
PT2727918T (pt) 2017-01-20
EP2470526A1 (en) 2012-07-04
LUC00101I2 (ar) 2020-01-23
US9314464B2 (en) 2016-04-19
US20230116233A1 (en) 2023-04-13
SI2470526T1 (sl) 2014-09-30
HRP20140799T1 (hr) 2014-11-07
EA201500175A1 (ru) 2015-05-29
US20130296318A1 (en) 2013-11-07
US8501758B2 (en) 2013-08-06
CU20120034A7 (es) 2012-06-21
CL2012000340A1 (es) 2012-08-17
US20180297985A1 (en) 2018-10-18
JP6045519B2 (ja) 2016-12-14
HUE032847T2 (hu) 2017-11-28
KR20120062839A (ko) 2012-06-14
ECSP23004573A (es) 2023-04-28
CO6612222A2 (es) 2013-02-01
CN103896921A (zh) 2014-07-02
CA2771775A1 (en) 2011-03-03
NZ598924A (en) 2013-07-26
BR112012004453A8 (pt) 2021-06-08
ES2492499T3 (es) 2014-09-09
US20160120866A1 (en) 2016-05-05
DK2727918T3 (da) 2017-01-23
GT201200053A (es) 2014-03-27
US9593099B2 (en) 2017-03-14
SMT201400133B (it) 2014-11-10
EA025222B1 (ru) 2016-12-30
CA2771775C (en) 2015-01-20
SI2727918T1 (sl) 2017-02-28
MX2012002546A (es) 2012-04-11
IN2012DN02469A (ar) 2015-08-21
AU2010286569B2 (en) 2013-10-10
AU2010286569C1 (en) 2019-11-28
MA33604B1 (ar) 2012-09-01
GEP20146102B (en) 2014-05-27
ECSP12011700A (es) 2012-03-30
US20160263113A1 (en) 2016-09-15
US20160280687A1 (en) 2016-09-29
DK2470526T3 (da) 2014-08-25
RS53489B1 (en) 2015-02-27
PL2470526T3 (pl) 2014-10-31
HUS1900013I1 (hu) 2019-04-29
IL218084A (en) 2016-11-30
NI201200029A (es) 2012-05-29
USRE49556E1 (en) 2023-06-20
BR112012004453B1 (pt) 2022-04-26
NO2019011I1 (no) 2019-03-05
SG178351A1 (en) 2012-03-29
NL300973I2 (nl) 2022-05-05
US20160122324A1 (en) 2016-05-05
LTC2470526I2 (lt) 2020-04-27
JP2014098022A (ja) 2014-05-29
EP2727918A1 (en) 2014-05-07
AR077975A1 (es) 2011-10-05
EA201200373A1 (ru) 2012-09-28
BR112012004453A2 (pt) 2021-03-09

Similar Documents

Publication Publication Date Title
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
PH12020550450A1 (en) Certain chemical entities, compositions and methods
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
MA32393B1 (ar) مركبات و تراكيب تعمل كمثبطات الكيناز
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
MX336611B (es) Inhibidores selectivos de glucosidasas y sus usos.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.